Response to combined modality treatment in a five-year survivor of extensive small cell lung cancer with severe complications

0Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

We present a rare case of a five-year survivor of small cell lung cancer with severe complications who responded to combined modality treatment. Prior to initial chemotherapy, he experienced severe complications including sepsis, pneumonia, ileus, and a performance status of 4. He was treated with an ileus tube and IVH, and was managed by mechanical ventilation for four days. After his general condition improved, he received combination chemotherapy of carboplatin, with the target area under the plasma concentration versus the time curve (AUC) of 5 mg· min/ml day 1, and etoposide (80 mg/m2) on days 1, 2, 3 for four courses, and complete remission (CR) was obtained. Six months later, systemic relapse occurred, but he achieved complete remission again with nine courses of CODE (cisplatin, vincristine, adriamycin, and etoposide) chemotherapy and sequential chest radiotherapy. Five years after the initial chemotherapy, the patient is alive and disease free.

Cite

CITATION STYLE

APA

Sawafuji, K., Okamoto, H., Nagatomo, A., Kunikane, H., Watanabe, K., & Nakamura, N. (2000). Response to combined modality treatment in a five-year survivor of extensive small cell lung cancer with severe complications. Internal Medicine, 39(6), 478–481. https://doi.org/10.2169/internalmedicine.39.478

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free